TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03899259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04461938

Intervention type: OTHER
Group type: OTHER
Intervention: Fasting
Description: The study intervention consists of one fasting cycle of 72 hours prior to biopsy/resection. Depending on clinical condition, patients can be hospitalized during the course of the study (e.g. need for medical assistance due to immobilization). Patients in good clinical condition will be admitted on day 3.
Study: NCT02876302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV (in the vein) weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV (in the vein) weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2, IV (in the vein) weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, IV (in the vein) every 14 days for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, IV (in the vein) every 14 days for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2, IV (in the vein) every 14 days for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, IV (in the vein) every 14 days for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, IV (in the vein) every 14 days for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, IV (in the vein) every 14 days for 4 doses.
Study: NCT00702273

Intervention type: DRUG
Intervention: 150 µg Corifollitropin Alfa
Description: On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.

Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 1 to 7)
Description: Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

Intervention type: DRUG
Intervention: Placebo for Corifollitropin Alfa
Description: Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.

Intervention type: DRUG
Intervention: Placebo for RecFSH/Follitropin beta
Description: Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)
Description: From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

Intervention type: DRUG
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG

Intervention type: DRUG
Intervention: Ganirelix
Description: On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG

Intervention type: BIOLOGICAL
Intervention: hCG
Description: When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Intervention: hCG
Description: When 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.

Intervention type: BIOLOGICAL
Intervention: Progesterone
Description: On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
Study: NCT04760327

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy with bleomycin or cisplatin
Description: Electrochemotherapy with cisplatin or bleomycin of gynecological cancers
Study: NCT01585805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor tissue and blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo tumor tissue and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor tissue and blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04410354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merimepodib
Description: 400 mg (total daily dose of 1200 mg) for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: 0 mg (total daily dose of 0 mg) for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: 200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: 200 mg loading dose on Day 0 followed by 100 mg daily dose for 4 days. If a subject does not demonstrate clinical improvement, 100 mg daily dose may be extended for up to 5 additional days (for a total of up to 10 days)
Study: NCT00613132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec, RAD001, and Hydroxyurea
Description: Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec, RAD001, and Hydroxyurea
Description: Dose of Gleevec will be 400 mg in 1st cohort \& will be increased to 600 mg po/day \& then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 \& hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
Study: NCT02214771

Intervention type: DRUG
Intervention: Fidaxomicin
Description: oral

Intervention type: DRUG
Intervention: Treatment for CDI other than fidaxomicin Type
Description: Oral
Study: NCT04345783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for injection, apatinib mesylate and tegio
Description: Camrelizumab for injection: fixed dose of 200 mg, ivgtt for 30 minutes, given on D1, repeat for every 3 weeks; Apatinib mesylate: 250 mg, p.o, qd; Tegio capsule: p.o., bid, D1-14, repeat for every 21 days.
Study: NCT02201147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold biopsy polypectomy
Description: removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: removal of eligible polyps using cold snare polypectomy technique

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy
Description: mini (10 mm open diameter) size electrosurgical snare without application of electrocautery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold biopsy polypectomy
Description: standard- capacity forceps with narrow band imaging endoscopy
Study: NCT00801450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Description: 40 mg
Study: NCT01334905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178
Description: oral
Study: NCT02709447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Date SMART
Description: Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: Psycho-educational group prevention program targeting knowledge and skills only
Study: NCT04814992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Preoperative CBT Intervention (PAINTrainer)
Description: Subjects will be asked to complete eight (8) 30- to 45-minute educational sessions during the 4 weeks prior to your surgery. In addition to the computer based training sessions, there is a motivational interviewing component that requires subjects to meet with a member of the study team weekly for a total of four (4) 30- to 45-minute meetings to help manage opioid medication use. It is expected that subject participation in this arm of the study will be a total of 12 hours over the course of the entire study.
Study: NCT00601471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal tibiofibular manipulation
Description: proximal tibiofibular manipulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distal tibiofibular manipulation
Description: distal tibiofibular manipulation

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: no intervention
Description: no intervention / control
Study: NCT02946827

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced low FODMAPs /gluten free diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Balanced gluten free diet
Study: NCT02865135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPX-E7 vaccine
Description: Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.
Study: NCT04891406

Intervention type: OTHER
Group type: OTHER
Intervention: E
Description: Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
Study: NCT02865135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPX-E7 vaccine
Description: Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPX-E7 vaccine
Description: Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.
Study: NCT00574171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1250mg by mouth daily one hour before or after breakfast on a continuous basis.
Study: NCT04891406

Intervention type: OTHER
Group type: OTHER
Intervention: E
Description: Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: E
Description: Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: E
Description: Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: E
Description: Use of product E (Marlboro Gold, conventional cigarette, 0.8 mg nicotine/cigarette) for approximately 5 minutes
Study: NCT03203408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSTENIL PLUS
Description: Injection into the joint cavity of the most painful knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYNVISC-ONE
Description: Injection into the joint cavity of the most painful knee
Study: NCT03839875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynomax® XL Vaginal Ovule
Description: tioconazole, tinidazole, lidocaine
Study: NCT03812562

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given IV
Study: NCT01772186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time somatosensory cue
Description: A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
Study: NCT01971762

Intervention type: BEHAVIORAL
Intervention: Follow recommendations based on scientific evidence to S. aureus bacteremia management

Intervention type: BEHAVIORAL
Intervention: Not to follow recommendations based on scientific evidence to S. aureus bacteremia management
Study: NCT01329926

Intervention type: PROCEDURE
Intervention: Harvesting of neural stem cells
Description: During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
Study: NCT03576755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone 100mg
Description: Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
Study: NCT01908933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeriSeal Emphysematous Lung Sealant Syst
Description: This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
Study: NCT02653170

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCM
Description: One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCM and VSSP
Description: SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~1. Biopsychosocial assessment of patient and caregiver needs.~2. Set up appointments.~3. Assist scheduling appointments with primary care physician and other medical providers.~4. Promote medication adherence through medication tool kits, pill organizers and other aids.~5. Facilitate patient and caregiver engagement and activation.~6. Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~1. Contact list of care team members.~2. Access to hospital patient portal.~3. Stroke education materials, resources, and guidelines.~4. Access to Michigan 2-1-1 services.~5. Medication information and adherence tools.~6. Patient and Caregiver support networks.
Study: NCT00083941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax
Description: 1ml intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Intravenous IL-2
Study: NCT04153890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FamPALcare
Description: Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care. FamPALcare intervention will be delivered by community-based nurses. FamPALcare intervention involves coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions.~The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines.
Study: NCT00574171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
Study: NCT01619540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver

Intervention type: OTHER
Group type: OTHER
Intervention: Valsalva maneuver
Study: NCT03826810

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: aPDT
Description: For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
Study: NCT03015181

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB075-00-AB
Description: VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.